SEC Form 4 · accession 0001723128-19-000009
Amneal Pharmaceuticals, Inc. · AMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David A Buchen
Officer — SVP, Chief Legal Officer
Period of report
Jan 3, 2019
Accepted (ET)
Jan 7, 2019 · 5:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001723128
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $13.58 | Jan 3, 2019 | A | 227,273 | A | — | Jan 3, 2029 | Class A Common Stock | 227,273 | 227,273 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 3, 2019 | A | 110,457 | A | — | — | Class A Common Stock | 110,457 | 110,457 | D |
Explanation of responses
- F1The option vests in four equal annual installments beginning on January 3, 2020.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- F3The restricted stock units vest in four equal annual installments beginning on January 3, 2020 and have no expiration date.